JPWO2021045159A1 - - Google Patents

Info

Publication number
JPWO2021045159A1
JPWO2021045159A1 JP2021544029A JP2021544029A JPWO2021045159A1 JP WO2021045159 A1 JPWO2021045159 A1 JP WO2021045159A1 JP 2021544029 A JP2021544029 A JP 2021544029A JP 2021544029 A JP2021544029 A JP 2021544029A JP WO2021045159 A1 JPWO2021045159 A1 JP WO2021045159A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544029A
Other languages
Japanese (ja)
Other versions
JP7692832B2 (ja
JPWO2021045159A5 (cg-RX-API-DMAC7.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021045159A1 publication Critical patent/JPWO2021045159A1/ja
Publication of JPWO2021045159A5 publication Critical patent/JPWO2021045159A5/ja
Priority to JP2025050332A priority Critical patent/JP2025094217A/ja
Application granted granted Critical
Publication of JP7692832B2 publication Critical patent/JP7692832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021544029A 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法 Active JP7692832B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050332A JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019161526 2019-09-04
JP2019161526 2019-09-04
PCT/JP2020/033463 WO2021045159A1 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050332A Division JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Publications (3)

Publication Number Publication Date
JPWO2021045159A1 true JPWO2021045159A1 (cg-RX-API-DMAC7.html) 2021-03-11
JPWO2021045159A5 JPWO2021045159A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7692832B2 JP7692832B2 (ja) 2025-06-16

Family

ID=74852211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544029A Active JP7692832B2 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Country Status (10)

Country Link
US (1) US20230119894A1 (cg-RX-API-DMAC7.html)
EP (2) EP4026564A4 (cg-RX-API-DMAC7.html)
JP (2) JP7692832B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220056219A (cg-RX-API-DMAC7.html)
CN (2) CN114585387B (cg-RX-API-DMAC7.html)
AU (1) AU2020341926B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003323A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151909A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002683A (cg-RX-API-DMAC7.html)
WO (1) WO2021045159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure
MX2023013662A (es) * 2021-09-02 2024-01-08 Daewoong Therapeutics Inc Composicion farmaceutica para prevenir o tratar una enfermedad ocular diabetica que comprende el inhibidor de sglt-2.
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
JP2015516419A (ja) * 2012-05-10 2015-06-11 イーライ リリー アンド カンパニー Sglt1阻害剤としてのピラゾール化合物
JP2018115216A (ja) * 2011-08-31 2018-07-26 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
JP7130588B2 (ja) * 2018-04-04 2022-09-05 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
JP7206132B2 (ja) * 2018-03-01 2023-01-17 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
JP2018115216A (ja) * 2011-08-31 2018-07-26 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
JP2015516419A (ja) * 2012-05-10 2015-06-11 イーライ リリー アンド カンパニー Sglt1阻害剤としてのピラゾール化合物
JP7206132B2 (ja) * 2018-03-01 2023-01-17 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
JP7130588B2 (ja) * 2018-04-04 2022-09-05 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Also Published As

Publication number Publication date
CN114585387B (zh) 2024-10-29
KR20220056219A (ko) 2022-05-04
JP7692832B2 (ja) 2025-06-16
US20230119894A1 (en) 2023-04-20
EP4026564A4 (en) 2023-03-15
BR112022003323A2 (pt) 2022-05-24
WO2021045159A1 (ja) 2021-03-11
EP4026564A1 (en) 2022-07-13
AU2020341926A1 (en) 2022-03-17
MX2022002683A (es) 2022-04-07
JP2025094217A (ja) 2025-06-24
CN114585387A (zh) 2022-06-03
CA3151909A1 (en) 2021-03-11
AU2020341926B2 (en) 2026-02-26
EP4342466A1 (en) 2024-03-27
CN119113123A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
BR112019017762A2 (cg-RX-API-DMAC7.html)
BR112019016141A2 (cg-RX-API-DMAC7.html)
AU2020104490A5 (cg-RX-API-DMAC7.html)
BR112021013944A2 (cg-RX-API-DMAC7.html)
BR112019016138A2 (cg-RX-API-DMAC7.html)
BR112019016142A2 (cg-RX-API-DMAC7.html)
BR112021012348A2 (cg-RX-API-DMAC7.html)
AT524962A5 (cg-RX-API-DMAC7.html)
BR112021013128A2 (cg-RX-API-DMAC7.html)
BR102019023359A2 (cg-RX-API-DMAC7.html)
BR102020025141B1 (pt) Máquina elétrica girante eletronicamente comutada
BR102020020846B1 (pt) Niveladora, e, método para serviço em uma niveladora
BR102020020816B1 (pt) Veículo, e, método para controlar o movimento de ar através de um veículo com uma ventoinha do veículo
BR102020018650B1 (pt) Método para preparar óxido de cálcio usando um forno pré- aquecedor de suspensão de múltiplos estágios
BR102020017390B1 (pt) Bomba multifásica
BR102020011722B1 (pt) Porta de tela para um pacote de radiadores
BR102020005984B1 (pt) Dispositivo de arranque-gerador combinado, e, conjunto de trem de acionamento
BR112021010564B1 (pt) Sistema de armadilha para animais e método de monitoramento do mesmo
BR112021014592B1 (pt) Compostos fotosensibilizadores, métodos de fabricação e aplicação em plantas
BR102020000355B1 (pt) Embreagem que tem dois estágios para aplicar torque variado entre um eixo de entrada e um eixo de saída
BR102019027339B1 (pt) Sistema de aspersão de água e difusor de sistema de aspersão de água
BR102019026575B1 (pt) Atuador, e, aeronave
BR102019026542B1 (pt) Sistema para detectar e controlar a posição de spoiler de asa de aeronave
BR102019026293B1 (pt) Sistema de aeronave, e, método para transmitir energia de um primeiro componente para um segundo componente
BR102019026215B1 (pt) Sinalizador acústico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250604

R150 Certificate of patent or registration of utility model

Ref document number: 7692832

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350